UNSPSC 51182057: Nandrolone cyclotate

This classification denotes a therapeutic androgen and anabolic steroid C28H38O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1MG9GW4ZH8, chemically known as estr-4-en-3-one, 17-(((4-methylbicyclo(2.2.2)oct-2-en-1-yl)carbonyl)oxy)-, (17.beta.)-, but more generally known as nandrolone cyclotate, which bears US NIH Compound Identifier 164526. Most nations, for tariff and trade purposes, schedule nandrolone cyclotate under HS 29372900 and SITC 54153. As of Q4 2014, NANDROLONE CYCLOTATE remains US FDA's Preferred Term for this commodity.

Nandrolone cyclotate bears US NLM identifiers UMLS ID C2828223 and NCI Concept Code C87228. SMILES: C[C@@]12C=C[C@@](CC1)(CC2)C(=O)O[C@@H]3[C@@]4([C@H]([C@H]5[C@@H]([C@@H]6C(=CC(=O)CC6)CC5)CC4)CC3)C.

UNSPSC 51182057 Nandrolone cyclotate is a Commodity code covering injectable anabolic steroid pharmaceuticals. State and local governments procure this product through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is a primary buyer under this code, issuing blanket master agreements with manufacturers to supply generic and branded pharmaceuticals to state and local health departments, correctional facilities, and other public healthcare institutions. Solicitations under this code require vendors to maintain FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance, and to supply products exclusively through authorized pharmaceutical wholesalers with established chargeback systems. Pricing structures vary — flat pricing, net price formats (NF30, NF60, NF90), or WAC-minus models are common — and vendors must carry substantial insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other alliance members. The RFP (Solicitation Number S1070000015802) closes March 26, 2026, with product availability required by May 15, 2026 and contract effectiveness July 1, 2026. Award criteria weight price competitiveness at 75 percent, fixed pricing and compliance factors at 20 percent combined, and EDI capability at 5 percent. Vendors must maintain relationships with at least two of three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and accept a 3 percent administrative fee on all purchases. Contract terms run two years for new vendors with optional extensions at MMCAP's discretion, with incumbent vendors' agreements extending through June 30, 2028.